NCT01186146

Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE)

Optimal Duration of Clopidogrel Therapy After Drug-Eluting Stent Implantation to Reduce Late Coronary Arterial Thrombotic Events

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 5,000 (actual)
• Sponsor: Seung-Jung Park · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is randomized-controlled trial to evaluate the difference of composite of cardiac death, myocardial infarction, or Stroke between the dual antiplatelet therapy group and the aspirin monotherapy group after 1-year of drug-eluting stents implantation.

Detailed description

This is subsequent clinical trial of previously published pooled analysis of the REAL-LATE and the ZEST-LATE Trial, in which nonsignificant higher trend for increased rate of death (all-cause and cardiac), myocardial infarction, or stroke in the dual antiplatelet therapy group compared to the aspirin monotherapy group was noted.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Aspirin monotherapy	stopping clopidogrel at 1 year after DES
DRUG	Aspirin,Clopidogrel	continue aspirin and clopidogrel 1year after DES

Timeline

• Start date: 2010-08-01
• Primary completion: 2012-12-01
• Completion: 2013-10-01
• First posted: 2010-08-23
• Last updated: 2014-03-20

Locations

19 sites across 1 country: South Korea